Fresenius Kabi has announced that it has received approval from the U.S. Food and Drug Administration to market Naropin (ropivacaine HCL Injection, USP) 0.2 percent 100mL and 200mL premix bags in the company’s proprietary Freeflex delivery system. These new...
READ MORE




